An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs TRx 0237 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Registrational
- Sponsors TauRx Therapeutics
- 12 Mar 2018 Status changed from recruiting to discontinued.
- 02 Aug 2017 This trial has been discontinued in Netherlands.
- 19 Jul 2017 This trial has been discontinued in Croatia (End date: 2017-05-08).